Motilon Injection 10 mg/2 ml

Motilon Injection, containing Metoclopramide Hydrochloride 10 mg/2 ml, is a prokinetic and anti-emetic medication manufactured by Synovia Pharma PLC. Priced at ৳3.77 per unit (10’s pack: ৳37.70), it addresses gastrointestinal motility disorders and chemotherapy-induced nausea. The injection form ensures rapid therapeutic action for acute conditions.

This medication blocks dopamine and serotonin receptors in the brain’s chemoreceptor zone, enhancing upper GI motility. It accelerates gastric emptying without stimulating secretions, making it effective for diabetic gastroparesis. Motilon Injection also increases lower esophageal sphincter pressure, reducing reflux symptoms.

Indications: Used for diabetic gastric stasis, postoperative nausea prevention, chemotherapy-induced vomiting, and facilitating small bowel intubation. It aids radiological examinations by improving barium transit. Dosage varies: 10 mg IV/IM for gastroparesis, 1-2 mg/kg for chemotherapy nausea, and 10-20 mg IM post-surgery.

Side effects include dysgeusia (23%), headache (10%), and fatigue (7%). Elderly patients require cautious dosing. Store at 20–25°C, protected from light. Contraindicated in gastrointestinal obstruction. Pregnant/nursing women should consult doctors despite its Category B classification.

Explore alternatives like Motilon 10 mg tablets or 5 mg/5 ml syrup. Always follow prescribed guidelines to minimize risks of tardive dyskinesia with prolonged use. For detailed pharmacology, visit the Metoclopramide profile.

Diabetic gastroparesis: 10 mg IV/IM 4 times daily (max 40 mg/day). Chemotherapy-induced emesis: 1-2 mg/kg IV every 2-3 hours. Postoperative: 10-20 mg IM. Administer IV doses over 1-15 minutes. Treatment duration: 2-8 weeks based on indication.

Most common adverse reactions (≥5%) are: dysgeusia, headache, and fatigue.

Pregnancy Category B: No fetal harm in animal studies. Human data limited. Excreted in breast milk; use cautiously during lactation.

Limit treatment to 12 weeks max to prevent tardive dyskinesia. Avoid in depression/Parkinson’s patients. Monitor liver function during prolonged therapy.

Reduce dose in geriatrics. Increase dosing interval to 24h in renal impairment. Monitor serum creatinine in hepatic dysfunction. Pediatric use restricted to intubation facilitation.